Terms: = Lung cancer AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA
137 results:
1. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract] [Full Text] [Related]
2. Real-world outcomes associated with afatinib use in patients with solid tumors harboring nrg1 gene fusions.
Liu SV; Frohn C; Minasi L; Fernamberg K; Klink AJ; Gajra A; Savill KMZ; Jonna S
Lung Cancer; 2024 Feb; 188():107469. PubMed ID: 38219288
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic and predictive biomarkers in non-small cell lung carcinoma.
Odintsov I; Sholl LM
Pathology; 2024 Mar; 56(2):192-204. PubMed ID: 38199926
[TBL] [Abstract] [Full Text] [Related]
4. Adipocyte Precursor-Derived nrg1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
[TBL] [Abstract] [Full Text] [Related]
5. Fluorescent in situ hybridization has limitations in screening nrg1 gene rearrangements.
Zhang X; Li L; Gao F; Liu B; Li J; Ren S; Peng S; Qiu W; Pu X; Ye Q
Diagn Pathol; 2024 Jan; 19(1):1. PubMed ID: 38173003
[TBL] [Abstract] [Full Text] [Related]
6. Analysis of CD74 Occurrence in Oncogenic Fusion Proteins.
Vargas J; Pantouris G
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958963
[TBL] [Abstract] [Full Text] [Related]
7. HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of cancer.
Majumder A
Cells; 2023 Oct; 12(21):. PubMed ID: 37947595
[TBL] [Abstract] [Full Text] [Related]
8. Pulmonary invasive mucinous adenocarcinoma.
Chang WC; Zhang YZ; Nicholson AG
Histopathology; 2024 Jan; 84(1):18-31. PubMed ID: 37867404
[TBL] [Abstract] [Full Text] [Related]
9. HER4 and EGFR Activate Cell Signaling in nrg1 Fusion-Driven cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract] [Full Text] [Related]
10. Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics.
Goto E; Takamochi K; Kishikawa S; Hayashi T; Ueda T; Hattori A; Fukui M; Matsunaga T; Suzuki K;
Lung Cancer; 2023 Oct; 184():107348. PubMed ID: 37619407
[TBL] [Abstract] [Full Text] [Related]
11. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-nrg1 fusion: a case report.
Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
[TBL] [Abstract] [Full Text] [Related]
12. Error mitigation enables PET radiomic cancer characterization on quantum computers.
Moradi S; Spielvogel C; Krajnc D; Brandner C; Hillmich S; Wille R; Traub-Weidinger T; Li X; Hacker M; Drexler W; Papp L
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3826-3837. PubMed ID: 37540237
[TBL] [Abstract] [Full Text] [Related]
13. Encouraging adherence in adolescents with asthma using financial incentives: An RCT.
Keyser HH; Brinton JT; Bothwell S; Camacho M; Kempe A; Szefler SJ
Pediatr Pulmonol; 2023 Oct; 58(10):2823-2831. PubMed ID: 37449768
[TBL] [Abstract] [Full Text] [Related]
14. Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer.
Tsakonas G; Tadigotla V; Chakrabortty SK; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Lung Cancer; 2023 Aug; 182():107292. PubMed ID: 37423059
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathological Characteristics of nrg1 Fusion-Positive Solid Tumors in Korean Patients.
Cha YJ; Lee C; Joo B; Kim KA; Lee CK; Shim HS
Cancer Res Treat; 2023 Oct; 55(4):1087-1095. PubMed ID: 37321274
[TBL] [Abstract] [Full Text] [Related]
16. A Contemporary Clinicopathologic Analysis of Patients With Renal Cell Carcinoma and Vena Cava Involvement.
Al-Rusan OM; Patil D; Master VA; Osunkoya AO
Int J Surg Pathol; 2024 Apr; 32(2):279-285. PubMed ID: 37306114
[TBL] [Abstract] [Full Text] [Related]
17. RNA Sequencing Identifies Novel nrg1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.
Severson E; Achyut BR; Nesline M; Pabla S; Previs RA; Kannan G; Chenn A; Zhang S; Klein R; Conroy J; Sausen M; Sathyan P; Saini KS; Ghosh A; Jensen TJ; Reddy P; Ramkissoon SH
J Mol Diagn; 2023 Jul; 25(7):454-466. PubMed ID: 37164276
[TBL] [Abstract] [Full Text] [Related]
18. Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer.
Hisakane K; Seike M; Sugano T; Matsuda K; Kashiwada T; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Kubota K; Gemma A
Gene; 2023 Mar; 857():147177. PubMed ID: 36623674
[TBL] [Abstract] [Full Text] [Related]
19. A case of multiple primary lung adenocarcinoma with a CD74-nrg1 fusion protein and HER2 mutation benefit from combined target therapy.
Chen K; Li W; Xi X; Zhong J
Thorac Cancer; 2022 Nov; 13(21):3063-3067. PubMed ID: 36096509
[TBL] [Abstract] [Full Text] [Related]
20. Pan-HER inhibitors overcome lorlatinib resistance caused by nrg1/HER3 activation in ALK-rearranged lung cancer.
Taniguchi H; Akagi K; Dotsu Y; Yamada T; Ono S; Imamura E; Gyotoku H; Takemoto S; Yamaguchi H; Sen T; Yano S; Mukae H
Cancer Sci; 2023 Jan; 114(1):164-173. PubMed ID: 36086904
[TBL] [Abstract] [Full Text] [Related]
[Next]
